SCHEMBL4635452

SCHEMBL4635452

NC(=O)c1ccc(N2CC3C(N)C3C2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.45
CHRNA10 Q9GZZ6 1/20 0.45
CHRNA9 Q9UGM1 1/20 0.45
DPP4 P27487 1/20 0.44
PREP P48147 1/20 0.44
DPP8 Q6V1X1 1/20 0.44
DPP9 Q86TI2 1/20 0.44
DPP7 Q9UHL4 1/20 0.44
GPR119 Q8TDV5 1/20 0.42
CHEK1 O14757 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
F2 P00734 1/20 0.39
PRSS1 P07477 1/20 0.39
PRSS2 P07478 1/20 0.39
PRSS3 P35030 1/20 0.39
TMPRSS6 Q8IU80 1/20 0.39
ST14 Q9Y5Y6 1/20 0.39
PARP10 Q53GL7 3/20 0.38
ALDH1A1 P00352 2/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25629582 0.85 CHRNA7 (0.47) CHRNA7CHRNA10CHRNA9DPP4PREP
SCHEMBL4895486 0.84 NPC1 (0.51) DPP4PREPDPP8DPP9DPP7
SCHEMBL4636690 0.80 DPP4 (0.47) DPP4KMT2AMEN1HTTMAPT
SCHEMBL4635410 0.78 SMYD3 (0.64) DPP4KMT2AMEN1MAPTTSHR
SCHEMBL4635913 0.77 HTT (0.54) DPP4PREPDPP8DPP9DPP7
SCHEMBL7400655 0.76 CHRNA7 (0.47) CHRNA7CHRNA10CHRNA9DPP4PREP
SCHEMBL2771145 0.76 MAPT (0.53) CHRNA7CHRNA10CHRNA9GPR119CHEK1
SCHEMBL17530499 0.76 CHRNA7 (0.47) CHRNA7CHRNA10CHRNA9DPP4PREP
SCHEMBL2635957 0.76 CHRNA7 (0.47) CHRNA7CHRNA10CHRNA9DPP4PREP
SCHEMBL2263367 0.75 GPR119 (0.55) CHRNA7CHRNA10CHRNA9GPR119CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2008-12-04 US disclosed
EP-1931633-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS Ranbaxy Laboratories Limited (IN) 2008-06-18 EP disclosed
WO-2007029086-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP8 CHRNA7 4001/4885CHRNA10 4268/4885CHRNA9 3610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.